CRISPR Therapeutics Quote - CRSP

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

47.89

Bid

47.88

Offer

47.95

Volume

1,504,259

45.85 Day's Range 48.00

43.42 52 Week Range 91.10

Market Cap

4.088B

Previous Close

46.29

Open

46.35

Last Trade

Last Trade Time

Financial Volume

US$ 71,147,042

VWAP

47.2971

Average Volume (3m)

1,321,065

Shares Outstanding

85,353,479

Dividend Yield

PE Ratio

-26.60

Earnings Per Share (EPS)

-1.8

Revenue

371.21M

Net Profit

-153.61M

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.crisprtx.com

Headquarters

Zug, Che

Founded

CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRSP. The last closing price for CRISPR Therapeutics was US$46.29. Over the last year, CRISPR Therapeutics shares have traded in a share price range of US$ 43.42 to US$ 91.10.

CRISPR Therapeutics currently has 85,353,479 shares in issue. The market capitalisation of CRISPR Therapeutics is US$3.95 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -26.60.

Overall Flow

Bearish

Net Premium

-59M

Calls / Puts

11.76%

Buys / Sells

137.50%

OTM / ITM

26.67%

Sweeps Ratio

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.34	0.715036803365	47.55	48.44	45.51	2147948	47.03435261	CS
4	-0.04	-0.083455038598	47.93	59.0693	45.51	1899005	49.45806634	CS
12	0.17	0.356244761106	47.72	59.0693	43.42	1321065	48.19899546	CS
26	-6.8	-12.4337173158	54.69	67.88	43.42	1297571	51.90800505	CS
52	-20.8	-30.2809724851	68.69	91.1	43.42	1684271	61.15987617	CS
156	-34.53	-41.895171075	82.42	91.1	37.55	1501091	60.18614908	CS
260	-11.55	-19.431359354	59.44	220.21	32	1426547	78.78784965	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PDYNPalladyne AI Corporation	US$ 4.59 (129.50%)	83M
QMCOQuantum Corporation	US$ 9.11 (126.62%)	39.41M
NANano Labs Ltd	US$ 8.26 (89.02%)	2.03M
XCURExicure Inc	US$ 18.60 (71.27%)	4.36M
SKKSKK Holdings Limited	US$ 1.75 (59.09%)	95.06M
AMIXAutonomix Medical Inc	US$ 6.21 (-54.07%)	897.51k
CETXCemtrex Inc	US$ 0.1146 (-41.74%)	22.89M
MSWMing Shing Group Holdings Ltd	5.90 (-35.52%)	417.08k
RMSGReal Messenger Corporation	US$ 3.09 (-26.25%)	305.85k
ENSCEnsysce Biosciences Inc	US$ 0.4414 (-25.49%)	3.93M
ELABElevai Labs Inc	US$ 0.0201 (-0.50%)	425.38M
NVDANVIDIA Corporation	US$ 141.95 (-3.22%)	236.51M
SMCISuper Micro Computer Inc	US$ 33.15 (11.62%)	159.61M
VRPXVirpax Pharmaceuticals Inc	US$ 0.5501 (-6.72%)	159.39M
SOUNSoundHound AI Inc	US$ 8.24 (18.05%)	107.91M